Zydus Lifesciences has introduced India’s first trivalent influenza vaccine, VaxiFluTM, to provide protection against seasonal flu. Zydus said VaxiFluTM is recommended for individuals aged six months and above. The trivalent influenza vaccine contains updated strains based on WHO’s annual surveillance to provide targeted protection during the current flu season.
Emphasising the need for stronger vaccination coverage, Sharvil Patel, Managing Director, Zydus Lifesciences said, “We believe that this will significantly reduce vaccine-preventable diseases and related complications in high-risk groups.”
Vaccine based on WHO recommendations
The new vaccine follows WHO’s 2025–26 guidelines for the Northern Hemisphere. It targets three recommended strains — A/Victoria/4897/2022 (H1N1)pdm09-like virus, A/Croatia/10136RV/2023 (H3N2)-like virus, and B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
WHO and the US Centers for Disease Control and Prevention (CDC) had advised removing the B/Yamagata strain, which has not been in circulation since 2020. Many countries, including the US, have already adopted the trivalent vaccine model.
Share price of Zydus Lifesciences
The share price of Zydus Lifesciences has gained marginally this month, rising 2.68 per cent so far in 2025. The company focuses on innovative healthcare solutions and aims to transform lives through discoveries in life sciences.
Zydus Lifesciences posted a consolidated net profit of Rs 1,466.8 crore, up 3.3 per cent year-on-year (from Rs 1,419.9 crore). Revenue from operations rose 5.9 per cent YoY to Rs 6,573.7 crore, thanks largely to new drug launches in the US, though it remained flat sequentially (Rs 6,527.9 crore in Q4). The US market accounted for 49 per cent of revenues, contributing Rs 3,181.7 crore (up 3 per cent YoY and 2 per cent QoQ). EBITDA stood at Rs 2,088.5 crore with a steady margin at 31.8 per cent.